An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent solid tumors, as well as clinical activity in participants with a subset of solid tumors and non-Hodgkin\'s lymphoma (NHL).
Epistemonikos ID: f2b0ffe14107e0c6929af0c2fdc023c97c8af15f
First added on: May 13, 2024